Foghorn Therapeutics (FHTX) Consolidated Net Income (2020 - 2025)
Historic Consolidated Net Income for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to -$16.5 million.
- Foghorn Therapeutics' Consolidated Net Income rose 1387.41% to -$16.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.0 million, marking a year-over-year increase of 1780.47%. This contributed to the annual value of -$86.6 million for FY2024, which is 1199.48% up from last year.
- As of Q3 2025, Foghorn Therapeutics' Consolidated Net Income stood at -$16.5 million, which was up 1387.41% from -$18.8 million recorded in Q2 2025.
- Foghorn Therapeutics' 5-year Consolidated Net Income high stood at -$14.3 million for Q3 2023, and its period low was -$30.5 million during Q1 2023.
- In the last 5 years, Foghorn Therapeutics' Consolidated Net Income had a median value of -$24.1 million in 2023 and averaged -$23.8 million.
- Its Consolidated Net Income has fluctuated over the past 5 years, first crashed by 6890.29% in 2021, then skyrocketed by 4433.23% in 2023.
- Foghorn Therapeutics' Consolidated Net Income (Quarter) stood at -$28.5 million in 2021, then dropped by 1.33% to -$28.9 million in 2022, then increased by 16.55% to -$24.1 million in 2023, then increased by 19.09% to -$19.5 million in 2024, then increased by 15.56% to -$16.5 million in 2025.
- Its last three reported values are -$16.5 million in Q3 2025, -$18.8 million for Q2 2025, and -$20.2 million during Q1 2025.